Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Total Non-Current Liabilities: 2012-2025

Historic Total Non-Current Liabilities for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Sep 2025 value amounting to $215.8 million.

  • Enanta Pharmaceuticals' Total Non-Current Liabilities fell 12.86% to $215.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $215.8 million, marking a year-over-year decrease of 12.86%. This contributed to the annual value of $215.8 million for FY2025, which is 12.86% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Total Non-Current Liabilities stood at $215.8 million for Q3 2025, which was down 2.59% from $221.5 million recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Total Non-Current Liabilities ranged from a high of $256.9 million in Q2 2023 and a low of $30.7 million during Q1 2021.
  • Over the past 3 years, Enanta Pharmaceuticals' median Total Non-Current Liabilities value was $236.6 million (recorded in 2024), while the average stood at $222.0 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first declined by 16.39% in 2022, then skyrocketed by 449.57% in 2023.
  • Over the past 5 years, Enanta Pharmaceuticals' Total Non-Current Liabilities (Quarterly) stood at $55.4 million in 2021, then dropped by 16.39% to $46.3 million in 2022, then skyrocketed by 409.83% to $236.0 million in 2023, then grew by 0.26% to $236.6 million in 2024, then declined by 12.86% to $215.8 million in 2025.
  • Its last three reported values are $215.8 million in Q3 2025, $221.5 million for Q2 2025, and $229.2 million during Q1 2025.